Capital Markets Day 2015

(Oslo, Norway, 23 September 2015) Bionor Pharma ASA (Bionor) (OSE:BIONOR), a Norwegian biopharmaceutical company focused on developing its proprietary therapeutic vaccine Vacc-4x for HIV, will host a Capital Markets Day for institutional and private investors and financial analysts in Oslo on 7 October 2015 at 12:00-15:30 CEST.

Bionor’s Chairman Russell Greig and CEO David Solomon will present the company’s strategy, current highlights and next steps for value creation. Other key personnel from Bionor and Dr. Lars Østergaard from Aarhus University Hospital will provide information on Bionor’s development plans for Vacc-4x and the REDUC study as well as recent trends in HIV care and possible pathways towards a functional HIV cure.

To kick off the event, Bionor will host a sandwich lunch with the opportunity to meet the company’s representatives.

Venue: Hotel Continental, Stortingsgata 24-26, 0117 Oslo, Norway
Date: 7 October 2015
Time: 12:00-15:30 CEST

Agenda

  • Meet the Management & sandwich lunch
  • Company update – strategy and current highlights
  • Understanding HIV – an introduction to the disease
  • Functional HIV cure and Bionor’s clinical approach
  • Anticipated path to market
  • Q&A session
  • Summary and next steps for value creation.

Registration
Please send an email to Lene Larsen at ll@bionorpharma.com stating your full name, company and contact phone number.

Kindly register no later than1 October 2015.

Webcast
The event will also be webcast live, and a replay as well as presentations will be available on Bionor’s website.

Announcement as PDF

Further information
Jørgen F. Ravn, VP Investor Relations & Communications, +45 20 30 39 03, jfr@bionorpharma.com

About Bionor
Bionor Pharma is a Norwegian biopharmaceutical company focused on developing its proprietary therapeutic vaccine, Vacc-4x, for human immunodeficiency virus (HIV), which, if left untreated, causes acquired immunodeficiency syndrome, (AIDS), in humans. Bionor Pharma has first mover potential to advance its therapeutic vaccine, Vacc-4x, in combination with other medicines, as part of a functional cure for HIV. Vacc-4x has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Bionor’s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the HDAC inhibitor romidepsin in the REDUC study. Bionor is headquartered in Oslo, Norway, and is listed on the Oslo stock exchange, under the ticker BIONOR. More information about Bionor is available at www.bionorpharma.com.